Abstract
Abstract : Breast cancer requires estrogen for its initiation and maintenance before progressing into a more aggressive stage. We proposed to study the role of estrogen receptor (ER) target genes in the promotion of breast cancer. To achieve this goal we generated a regulable repressor KEDPK to directly turn-off the expression of ER target genes. The KEDPK contains an ER-DBD that recognizes the ERE elements of ER target genes, a KRAB repressive domain which can silence target genes when tethered to the promoter region and a mutated PR-LED which responds only to exogenous ligand. The KEDPK shows dose- dependent inhibition of ER target genes in transient transfections. The inhibitory activity of KEDPK is under the control of its ligand RU486 and is specific to ER target genes. Currently we have devoted our effort to generate stable cell lines expressing KEDPK and determine its ability to suppress the endogenous ER target genes. The success of developing these repressors will allow us to study the role of ER target genes in breast cancer progression. Results obtained in these studies will be highly relevant to efforts in optimization of current hormone therapy and gene therapy for breast cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
